



MEDICAMENTS LTD.

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

August 13, 2021

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Outcome of Board Meeting**

Dear Sir / Madam,

1. This is to inform you that, the Board of Directors of the Company at its meeting held on Friday, August 13, 2021 inter alia, has considered and approved the following:
 - A. Unaudited Standalone Financial Results along with limited review report for the quarter ended June 30, 2021
 - B. Book Closure dates from September 24, 2021 till September 26, 2021 for the purpose of Annual General Meeting
 - C. In view of the COVID-19 pandemic the 30th AGM of the Company will be held on Thursday, September 30, 2021 at 10.00 a.m. (IST), through VC/OAVM facility provided by Bigshare Services Pvt Ltd, Register and Transfer Agent of the company, to transact the business as set out in the Notice convening the AGM.
 - D. The e-voting period begins on September 27, 2021 at 10.00 a.m. and ends on September 29, 2021 at 5.00 p.m. During this period, shareholders of the Company holding shares as on the cut-off date i.e. September 23, 2021, may cast their vote electronically. The facility for e-voting will also be made available during the AGM to those members who could not cast their vote(s) by remote e-voting.



MEDICAMENTS LTD.

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com

CIN: L74110MH1991PLC326598 | **Tel:** +91 9167469649

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**



Abha Kapoor

Director (Finance) and CFO

DIN – 02799429

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2021

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for the previous year ended
		30-Jun-2021	31-Mar-2021	30-Jun-2020	31-Mar-2021
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	69.61	29.75	0.00	48.50
II	Other Income	0.00	0.00	0.00	0.00
III	Total Income (I + II)	69.61	29.75	0.00	48.50
IV	Expenses:				
	Cost of Materials Consumed	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	50.07	8.26	0.00	8.26
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00
	Employee benefits Expense	0.77	16.45	0.60	19.54
	Finance Costs	0.01	0.03	0.00	0.04
	Depreciation & amortisation expense	0.04	0.04	0.00	0.16
	Other Expenses	17.81	4.27	0.00	19.68
	Total Expenses (IV)	68.70	29.05	0.60	47.68
V	Profit / (loss) before exceptional items and tax (III-IV)	0.91	0.70	-0.60	0.82
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax (V-VI)	0.91	0.70	-0.60	0.82
VIII	Tax Expense:				
	(1) Current tax	0.20	0.25	0.00	0.25
	(2) Deferred tax	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	0.71	0.45	-0.60	0.57
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	0.71	0.45	-0.60	0.57
XIV	Other comprehensive income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss				
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	0.71	0.45	-0.60	0.57
XVI	Earnings per equity share (for continuing operation):				
	(1) Basic	0.01	0.01	0.00	0.01
	(2) Diluted	0.01	0.01	0.00	0.01
XVII	Earnings per equity share (for discontinued operation):				
	(1) Basic				
	(2) Diluted	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):				
	(1) Basic	0.01	0.01	0.00	0.01
	(2) Diluted	0.01	0.01	0.00	0.01
	NOTES:				
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.				
2	The result is provisional and unaudited and subject to change, regrouping and restatement.				

For Rubra Medicaments Limited

Place: Mumbai
Date:- August 13, 2021


 Abha Kapoor
 Director (Finance) & CFO
 DIN: 02799429



DD & COMPANY

CHARTERED ACCOUNTANTS

The Limited Review Report for listed entities other than banks and insurance companies - unaudited standalone quarterly and year to date results

Review Report

To,
The Board of Directors
Rubra Medicaments Limited
Mumbai

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Limited for the period ended June 30, 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Date: August 13, 2021

For M/s DD & Company
Chartered Accountants
Firm Registration No: FRN 129273W



Proprietor
Membership No: 045393
UDIN: 21045393AAAABH1732